ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Modella AI has signed a multi-year agreement with AstraZeneca for expediting AI-driven oncology clinical development.

AstraZeneca’s anselamimab has failed to show any benefit in patients with light chain amyloidosis in two Phase III trials.

AstraZeneca PLC (NASDAQ:AZN) is one of the 10 best defensive stocks to buy in a volatile market. On July 4, the company ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

AstraZeneca’s CARES phase III clinical programme of anselamimab in light chain amyloidosis fails to meet primary endpoint: Cambridge, UK Thursday, July 17, 2025, 09:00 Hrs [IST] ...

Manufacturing companies are particularly attentive to drugs designated as breakthrough therapies due to the accelerated market access and higher returns on investment. Breakthrough therapy drugs often ...

Sino Biopharmaceutical is acquiring the remaining stake in LaNova Medicines for US $950.9 million to bolster its cancer drug ...

They are the backbone of AI-powered biomedical discovery and mark the first step toward fully autonomous AI agents," said Jill Stefanelli, CEO of Modella AI. "Our state-of-the-art multimodal ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...